✦ LIBER ✦

Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma

✍ Scribed by Powell, Alex; Creaney, Jenette; Broomfield, Steven; Van Bruggen, Ivonne; Robinson, Bruce

Book ID: 119319363
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 319 KB
Volume: 52
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2006.01.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy for leukemia with a GM-CSF-produ

Therapy for leukemia with a GM-CSF-producing tumor cell vaccine

✍ Zhou Xing MD PhD 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 21 KB

Replication-defective recombinant Semlik

Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines

✍ Withoff, S; Glazenburg, K L; van Veen, M L; Kraak, M M J; Hospers, G A P; Störke 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

A phase-I clinical study of autologous t

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer

✍ Hendrik Veelken; Andreas Mackensen; Michael Lahn; Gabriele Köhler; Daniel Becker 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 257 KB 👁 2 views

Tumor cells transfected to express immunostimulatory cytokines, or admixed with similarly modified bystander cells, are able to induce immune responses against unmodified tumor cells in animal models. For treatment of human patients, a vaccine composed of autologous tumor cells and IL-2-secreting al

A phase-I Trial Using a Universal GM-CSF

A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease

✍ Sophie Dessureault; David Noyes; David Lee; Mary Dunn; William Janssen; Alan Can 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 727 KB

A phase II trial of vaccination with aut

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

✍ Lorenzo Pilla; Roberto Patuzzo; Licia Rivoltini; Michele Maio; Elisabetta Pennac 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 454 KB

A Phase II Study of Plerixafor (AMD3100)

A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma

✍ Amanda Cashen; Sandra Lopez; Feng Gao; Gary Calandra; Ron MacFarland; Karin Bade 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 281 KB